Introduction: During extracorporeal membrane oxygenation (ECMO) systemic anticoagulation with unfractionated heparin (UFH) is standard-of-care. However, there is uncertainty regarding optimal anticoagulation monitoring strategies.

Methods: We retrospectively investigated venovenous and venoarterial ECMO patients at the medical ICUs at the Medical University of Graz, Austria. We analyzed the correlation and concordance of R-time in thromboelastography (TEG), activated partial thromboplastin time (aPTT), and anti-Xa activity. The proportion within target range, the association of coagulation parameters above or below target range (aPTT 54-72 s; equals 1.5-2× upper limit of normal (ULN), anti-Xa activity 0.2-0.5 U/mL, and R-time in assays without heparinase 675-900 s; equals 1.5-2× ULN) with mortality, bleeding events and thrombotic complications were investigated.

Results: We analyzed 671 clusters of simultaneously performed coagulation tests in 85 ECMO cases that fulfilled inclusion criteria. Median age of patients was 57 years and 32% were female. There were poor correlations between the three coagulation tests and the proportion of discordance was 46%. Within the target range were 21% of R-time, 15% of aPTT, and 44% of anti-Xa activity measurements. Singular and multiple bleeding events occurred in 25 and 32 patients, respectively. The most common bleeding locations were catheter and cannula insertion sites followed by pulmonary hemorrhage. In VA-ECMO, anti-Xa activity was associated (OR 1.03 [1.01-1.06], p = 0.005) and correlated with bleeding events (spearman rho 0.49, p = 0.002; point biserial 0.49, p = 0.001). aPTT level below target range was associated with reduced mortality (OR 0.98 [0.97-0.99], p = 0.024). Thrombotic events occurred in six patients with no association of coagulation tests.

Conclusion: There was a high rate of discordance and poor correlation between aPTT, anti-Xa activity and R-time in TEG in ECMO patients. We found high rates of bleeding events and in VA-ECMO an association with elevated anti-Xa activity levels.

Download full-text PDF

Source
http://dx.doi.org/10.1177/08850666241313357DOI Listing

Publication Analysis

Top Keywords

anti-xa activity
24
target range
16
bleeding events
16
coagulation tests
12
anticoagulation monitoring
8
extracorporeal membrane
8
membrane oxygenation
8
oxygenation ecmo
8
ecmo patients
8
aptt anti-xa
8

Similar Publications

Context.—: Activated clotting time (ACT) is useful for monitoring heparin therapy in neurointerventional radiology (NIR). We previously used the Hemochron Signature Elite instrument for measuring ACT in NIR.

View Article and Find Full Text PDF

Monitoring unfractionated heparin (UFH) to ensure effective anticoagulation may be performed using anti-factor Xa activity (anti-Xa) instead of the activated partial thromboplastin time. However, in patients who have been treated with oral factor Xa (FXa) inhibitors (apixaban, rivaroxaban, and edoxaban) while switching to UFH therapy, there is a risk that these oral anti-FXa drugs could interfere with UFH calibrated anti-Xa monitoring. This may lead to inappropriate anticoagulation management.

View Article and Find Full Text PDF

Discrepancy between parallel anti-Xa and APTT is related to mortality in patients with Impella™ supported cardiogenic shock.

J Thromb Haemost

March 2025

Heart Center, OLV Aalst, Aalst, Belgium; Department of Cardiology and Cardiac Intensive Care, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Division of Anaesthetics, Pain Medicine and Intensive Care, Faculty of Medicine, Imperial College, London, United Kingdom. Electronic address:

Background: Managing unfractionated heparin (UFH) during percutaneous mechanical circulatory support (PMCS) for cardiogenic shock (CS) is challenging due potential discrepancies between coagulation tests.

Objectives: To study the causes and consequences of discrepancies between anti-Xa and activated partial thromboplastin time (APTT) for UFH-monitoring during micro-axial flow pump support (Impella™) for CS.

Patients/methods: We assessed patients in CS supported with Impella™ in two tertiary care centres over 62 months.

View Article and Find Full Text PDF

This study compared the efficacy of therapeutic anticoagulation guided by anti-Xa levels vs. a D-dimer-based protocol in ICU patients with COVID-19. Given the heightened risk of thrombosis despite anticoagulation therapy in some cases, we hypothesised that anti-Xa measurement improves anticoagulation effectiveness and clinical outcomes in this population.

View Article and Find Full Text PDF

Cerebral venous thrombosis (CVT) is a rare, potentially life-threatening condition that occurs when blood clots form in the venous sinuses of the brain, leading to impaired venous drainage, increased intracranial pressure, and neurological deficits. We discuss the case of a 32-year-old female who presented with a four-day history of worsening headache, nausea, vomiting, and right-sided weakness. She was on oral contraceptive pills (OCPs) for two years for menstrual regulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!